Session 117

HR 5623

The Insulin Cost Reduction Act

In Committee

Jurisdiction

US Congress

Session

Session 117

Official source

Chamber

House

Session

Session 117

Jurisdiction

US Congress

Bill overview

This bill, the Insulin Cost Reduction Act, aims to lower the cost of insulin for Medicare beneficiaries. It prohibits private insurance plans and Medicare from negotiating lower insulin prices with manufacturers unless those discounts are offered directly to patients at the pharmacy or reflected in higher patient cost-sharing amounts. The goal is to ensure that people with diabetes have access to affordable insulin medication. This legislation focuses specifically on insulin drugs, as defined by the Secretary of Health and Human Services.

Positions across the country

No public positions recorded for this legislation.

Arguments in favor

Reasons to support this legislation.

No arguments in favor have been submitted.

Submit yours

Arguments opposed

Reasons to oppose this legislation.

No arguments opposed have been submitted.

Submit yours

Legislative history

2021-10-19House

Referred to the Subcommittee on Health.

2021-10-19House

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2021-10-19House

2021-10-19

Introduced in House

Read the latest version inline or switch to a previous version.

HR 5623

Bill overview

Sponsors

Primary sponsor

Cosponsors

Positions across the country

Arguments in favor

Arguments opposed

Bill text

Positions across the country